Sertraline for the treatment of depression in Parkinson's disease.
Identifieur interne : 004595 ( PubMed/Curation ); précédent : 004594; suivant : 004596Sertraline for the treatment of depression in Parkinson's disease.
Auteurs : R A Hauser [États-Unis] ; T A ZesiewiczSource :
- Movement disorders : official journal of the Movement Disorder Society [ 0885-3185 ] ; 1997.
English descriptors
- KwdEn :
- 1-Naphthylamine (analogs & derivatives), 1-Naphthylamine (therapeutic use), Aged, Antidepressive Agents, Second-Generation (therapeutic use), Antiparkinson Agents (therapeutic use), Depression (complications), Depression (drug therapy), Drug Interactions, Drug Therapy, Combination, Humans, Parkinson Disease (complications), Parkinson Disease (drug therapy), Pilot Projects, Prospective Studies, Selegiline (therapeutic use), Serotonin Uptake Inhibitors (therapeutic use), Sertraline, Severity of Illness Index, Treatment Outcome.
- MESH :
- chemical , analogs & derivatives : 1-Naphthylamine.
- chemical , therapeutic use : 1-Naphthylamine, Antidepressive Agents, Second-Generation, Antiparkinson Agents, Selegiline, Serotonin Uptake Inhibitors.
- complications : Depression, Parkinson Disease.
- drug therapy : Depression, Parkinson Disease.
- Aged, Drug Interactions, Drug Therapy, Combination, Humans, Pilot Projects, Prospective Studies, Sertraline, Severity of Illness Index, Treatment Outcome.
Abstract
Although antidepressant medications are commonly used to treat depression in Parkinson's disease (PD), little information is available regarding their safety and efficacy in this condition. Sertraline is a relatively selective serotonin reuptake inhibitor with some dopamine reuptake inhibitor activity. It has a favorable tolerability profile, especially in the elderly. We undertook an open-label pilot evaluation of the safety and efficacy of sertraline to treat depression in PD. A total of 15 patients with PD and depression participated in the study. Sertraline was introduced at a daily dose of 25 mg for 1 week and then increased to 50 mg/day. Patients underwent evaluation at baseline and at a final visit approximately 7 weeks later. Sertraline was generally well tolerated, but five patients experienced side effects, and two discontinued medication. Patients taking selegiline experienced more adverse effects. Beck Depression Inventory scores improved significantly (mean +/- SE = 16.0 +/- 2.0 vs 11.7 +/- 1.9, p = 0.03), and Unified Parkinson's Disease Rating Scale and energy-level scores were unchanged. These results suggest that sertraline may be a useful treatment for depression in PD. As substantial placebo effects can occur in studies of PD and depression, placebo-controlled, double-blind studies are warranted.
DOI: 10.1002/mds.870120522
PubMed: 9380061
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :004595
Links to Exploration step
pubmed:9380061Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Sertraline for the treatment of depression in Parkinson's disease.</title><author><name sortKey="Hauser, R A" sort="Hauser, R A" uniqKey="Hauser R" first="R A" last="Hauser">R A Hauser</name><affiliation wicri:level="1"><nlm:affiliation>Department of Neurology, University of South Florida, Tampa, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurology, University of South Florida, Tampa</wicri:regionArea></affiliation></author><author><name sortKey="Zesiewicz, T A" sort="Zesiewicz, T A" uniqKey="Zesiewicz T" first="T A" last="Zesiewicz">T A Zesiewicz</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="1997">1997</date><idno type="RBID">pubmed:9380061</idno><idno type="pmid">9380061</idno><idno type="doi">10.1002/mds.870120522</idno><idno type="wicri:Area/PubMed/Corpus">004595</idno><idno type="wicri:Area/PubMed/Curation">004595</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Sertraline for the treatment of depression in Parkinson's disease.</title><author><name sortKey="Hauser, R A" sort="Hauser, R A" uniqKey="Hauser R" first="R A" last="Hauser">R A Hauser</name><affiliation wicri:level="1"><nlm:affiliation>Department of Neurology, University of South Florida, Tampa, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurology, University of South Florida, Tampa</wicri:regionArea></affiliation></author><author><name sortKey="Zesiewicz, T A" sort="Zesiewicz, T A" uniqKey="Zesiewicz T" first="T A" last="Zesiewicz">T A Zesiewicz</name></author></analytic><series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title><idno type="ISSN">0885-3185</idno><imprint><date when="1997" type="published">1997</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>1-Naphthylamine (analogs & derivatives)</term><term>1-Naphthylamine (therapeutic use)</term><term>Aged</term><term>Antidepressive Agents, Second-Generation (therapeutic use)</term><term>Antiparkinson Agents (therapeutic use)</term><term>Depression (complications)</term><term>Depression (drug therapy)</term><term>Drug Interactions</term><term>Drug Therapy, Combination</term><term>Humans</term><term>Parkinson Disease (complications)</term><term>Parkinson Disease (drug therapy)</term><term>Pilot Projects</term><term>Prospective Studies</term><term>Selegiline (therapeutic use)</term><term>Serotonin Uptake Inhibitors (therapeutic use)</term><term>Sertraline</term><term>Severity of Illness Index</term><term>Treatment Outcome</term></keywords><keywords scheme="MESH" type="chemical" qualifier="analogs & derivatives" xml:lang="en"><term>1-Naphthylamine</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>1-Naphthylamine</term><term>Antidepressive Agents, Second-Generation</term><term>Antiparkinson Agents</term><term>Selegiline</term><term>Serotonin Uptake Inhibitors</term></keywords><keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Depression</term><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Depression</term><term>Parkinson Disease</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Drug Interactions</term><term>Drug Therapy, Combination</term><term>Humans</term><term>Pilot Projects</term><term>Prospective Studies</term><term>Sertraline</term><term>Severity of Illness Index</term><term>Treatment Outcome</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Although antidepressant medications are commonly used to treat depression in Parkinson's disease (PD), little information is available regarding their safety and efficacy in this condition. Sertraline is a relatively selective serotonin reuptake inhibitor with some dopamine reuptake inhibitor activity. It has a favorable tolerability profile, especially in the elderly. We undertook an open-label pilot evaluation of the safety and efficacy of sertraline to treat depression in PD. A total of 15 patients with PD and depression participated in the study. Sertraline was introduced at a daily dose of 25 mg for 1 week and then increased to 50 mg/day. Patients underwent evaluation at baseline and at a final visit approximately 7 weeks later. Sertraline was generally well tolerated, but five patients experienced side effects, and two discontinued medication. Patients taking selegiline experienced more adverse effects. Beck Depression Inventory scores improved significantly (mean +/- SE = 16.0 +/- 2.0 vs 11.7 +/- 1.9, p = 0.03), and Unified Parkinson's Disease Rating Scale and energy-level scores were unchanged. These results suggest that sertraline may be a useful treatment for depression in PD. As substantial placebo effects can occur in studies of PD and depression, placebo-controlled, double-blind studies are warranted.</div></front></TEI><pubmed><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">9380061</PMID><DateCreated><Year>1997</Year><Month>11</Month><Day>07</Day></DateCreated><DateCompleted><Year>1997</Year><Month>11</Month><Day>07</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0885-3185</ISSN><JournalIssue CitedMedium="Print"><Volume>12</Volume><Issue>5</Issue><PubDate><Year>1997</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Movement disorders : official journal of the Movement Disorder Society</Title><ISOAbbreviation>Mov. Disord.</ISOAbbreviation></Journal><ArticleTitle>Sertraline for the treatment of depression in Parkinson's disease.</ArticleTitle><Pagination><MedlinePgn>756-9</MedlinePgn></Pagination><Abstract><AbstractText>Although antidepressant medications are commonly used to treat depression in Parkinson's disease (PD), little information is available regarding their safety and efficacy in this condition. Sertraline is a relatively selective serotonin reuptake inhibitor with some dopamine reuptake inhibitor activity. It has a favorable tolerability profile, especially in the elderly. We undertook an open-label pilot evaluation of the safety and efficacy of sertraline to treat depression in PD. A total of 15 patients with PD and depression participated in the study. Sertraline was introduced at a daily dose of 25 mg for 1 week and then increased to 50 mg/day. Patients underwent evaluation at baseline and at a final visit approximately 7 weeks later. Sertraline was generally well tolerated, but five patients experienced side effects, and two discontinued medication. Patients taking selegiline experienced more adverse effects. Beck Depression Inventory scores improved significantly (mean +/- SE = 16.0 +/- 2.0 vs 11.7 +/- 1.9, p = 0.03), and Unified Parkinson's Disease Rating Scale and energy-level scores were unchanged. These results suggest that sertraline may be a useful treatment for depression in PD. As substantial placebo effects can occur in studies of PD and depression, placebo-controlled, double-blind studies are warranted.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hauser</LastName><ForeName>R A</ForeName><Initials>RA</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of South Florida, Tampa, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zesiewicz</LastName><ForeName>T A</ForeName><Initials>TA</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>UNITED STATES</Country><MedlineTA>Mov Disord</MedlineTA><NlmUniqueID>8610688</NlmUniqueID><ISSNLinking>0885-3185</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018687">Antidepressive Agents, Second-Generation</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000978">Antiparkinson Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017367">Serotonin Uptake Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>14611-51-9</RegistryNumber><NameOfSubstance UI="D012642">Selegiline</NameOfSubstance></Chemical><Chemical><RegistryNumber>9753I242R5</RegistryNumber><NameOfSubstance UI="D015057">1-Naphthylamine</NameOfSubstance></Chemical><Chemical><RegistryNumber>QUC7NX6WMB</RegistryNumber><NameOfSubstance UI="D020280">Sertraline</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Mov Disord. 1998 May;13(3):622</RefSource><PMID Version="1">9613775</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015057">1-Naphthylamine</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000031">analogs & derivatives</QualifierName><QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D018687">Antidepressive Agents, Second-Generation</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000978">Antiparkinson Agents</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D003863">Depression</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000150">complications</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D004347">Drug Interactions</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D004359">Drug Therapy, Combination</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D010300">Parkinson Disease</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000150">complications</QualifierName><QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D010865">Pilot Projects</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D011446">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D012642">Selegiline</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D017367">Serotonin Uptake Inhibitors</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D020280">Sertraline</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D012720">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D016896">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1997</Year><Month>9</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1997</Year><Month>9</Month><Day>26</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1997</Year><Month>9</Month><Day>26</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">9380061</ArticleId><ArticleId IdType="doi">10.1002/mds.870120522</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 004595 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 004595 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= PubMed
|étape= Curation
|type= RBID
|clé= pubmed:9380061
|texte= Sertraline for the treatment of depression in Parkinson's disease.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:9380061" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \
| NlmPubMed2Wicri -a MovDisordV3
| This area was generated with Dilib version V0.6.23. |  |